ما هو الفرق بين حقن مونجارو وأوزومبيك وهل يتم استخدامهم للتخسيس

Ozempic and Mounjaro Both Ozempic and Mounjaro are prescription medications used, along with diet and exercise, to help control blood sugar (glucose) levels in adults with type 2 diabetes. The difference between Ozempic and Mounjaro in terms of uses: Both medications are approved to be used, along with diet and exercise, to help control blood sugar levels in adults with type 2 diabetes. However, Ozempic is also approved to reduce the risk of a major cardiovascular event (such as a heart attack or stroke) in people with type 2 diabetes. Mounjaro, on the other hand, is not yet approved for this purpose. Are Ozempic and Mounjaro approved for weight loss? Ozempic and Mounjaro may also lead to significant weight loss, but they are not specifically approved by the FDA for this use. However, if weight loss is your only goal, another medication containing the active ingredient semaglutide, called Wegovy, is approved for weight loss (but not for blood sugar control in type 2 diabetes). How do Ozempec and Mongaro affect A1C? Yes, both medications can also help you reach your target A1C, which can prevent diabetes complications such as cardiovascular disease, nerve damage, kidney failure, and vision loss. Your blood sugar levels may start to decrease immediately, but it can take two to three months to reach your target A1C. A1C is a simple blood test that shows the average amount of sugar (glucose) in your blood over the past two to three months, giving you an idea of ​​your long-term diabetes control. What is the difference between Ozempec and Mongaro in terms of drug class? Both Ozempec and Mongaro fall into a class of drugs known as incretin mimetics, but there are some differences. Mongaro works Mounjaro affects both GLP-1 and GIP receptors, while Ozempic only affects GLP-1 receptors. However, both medications are effective treatments for type 2 diabetes. The differences between them are as follows: Ozempic: Contains the active ingredient semaglutide (made by Novo Nordisk). It is a GLP-1 receptor agonist (glucagon-like peptide-1), which stimulates the release of insulin from the pancreas when needed. It also slows the speed at which food moves through the digestive system. This can help you feel fuller for longer, reduce your food intake, and lead to weight loss. "These medications should not be used together or with other GLP-1 or GIP receptor agonists." How are Ozempic and Mounjaro given? Both Ozempic and Mounjaro are given as weekly subcutaneous (under the skin) injections in the stomach (abdomen), thigh, or upper arm. You or your caregiver can learn to give these injections at home using an injection pen. As follows: 1. The recommended starting dose of Mounjaro is 2.5 mg subcutaneously once weekly, increasing to 5 mg once weekly after 4 weeks. The maximum dose is 15 mg subcutaneously once weekly. 2. The recommended starting dose of Ozempic is 0.25 mg administered subcutaneously once weekly. After 4 weeks, the dose is increased to 0.5 mg once weekly. The maximum recommended dose of Ozempic is 2 mg weekly. Always start with low doses to help prevent common stomach side effects such as nausea, vomiting, decreased appetite, or diarrhea. Other common stomach side effects may include constipation, indigestion, and stomach pain. Which is more effective, Ozempic or Mounjaro? Mounjaro was compared with Ozempic for 40 weeks with over 1,870 participants. Researchers sought to determine how these medications affected the reduction of HbA1c levels and weight. Missing. Munjaro reduced HbA1c by 2% to 2.3% compared to 1.9% in participants injected with Ozempic. Munjaro also resulted in an average weight loss of 7.7 kg to 11.4 kg, compared to 5.9 kg in participants injected with Ozempic. It should be noted that Ozempic is now approved at a higher dose of 2 mg, and effectiveness may differ from Mounjaro at this higher dose. How do the side effects of Ozempic and Mounjaro compare? Gastrointestinal (digestive) side effects are the most common side effects of both Mounjaro and Ozempic. Gastrointestinal side effects are more common when starting the doses. Side effects: Mounjaro In the Mounjaro studies, the most commonly reported side effects, compared to placebo (inactive agent), were: Nausea: 12% to 18% Diarrhea: 12% to 17% Lossed appetite: 5% to 11% Vomiting: 5% to 9% Constipation: 6% to 7% Indigestion: 5% to 8% Stomach (abdominal) pain: 5% to 6% (vs. 4% on placebo) Other reported side effects of Mounjaro included hypoglycemia, increased heart rate, allergic reactions, and injection site reactions. Side effects: Ozempic The most common side effects with Ozempic are: Nausea: 16% to 20% Diarrhea: 8.5% to 9% Vomiting: 5% to 9% Constipation: 3% to 5% (Indigestion): 2.7% to 3.5% Stomach (abdominal) pain: 6% to 7% (vs. 4.6%) (Placebo) Other reported side effects of Ozempic include: hypoglycemia, injection site reactions, elevated amylase and lipase enzymes, gallstones, increased heart rate...